Table 2 The global RNA interference pipeline*
Sponsor | Program (clinical stage) | Status | Target | Indication | Number enrolled |
|---|---|---|---|---|---|
Alnylam/Cubist/Kyowa Kirin | ALN-RSV (phase IIb) | Ongoing | RSV nucleocapsid | Adult RSV infection | 354 |
Pfizer/Quark | PF-04523655 (phase II) | Ongoing | RTP801 | (1)AMD, diabetic macular edema | 244†|
Quark | QPI 1002 (phase II) | Ongoing | p53 | (1)Acute kidney injury, delayed graft function | 56†|
Zabecor | Excellair (phase II) | Ongoing | Syk kinase | Asthma | ? |
Alnylam | ALN-VSP (phase I) | Ongoing | VEGF, KSP | Primary and secondary liver cancer | 55†|
Calando | CALAA-01 (phase I) | Ongoing | RRM2 | Cancer | 36†|
Silence | Atu-027 (phase I) | Ongoing | PKN3 | Cancer (GI, lung other) | 33†|
Sylentis | SYL040012 (phase I) | Ongoing | β2 adrenergic receptor | Glaucoma | ? |
Alnylam | ALN-TTR (phase I) | Ongoing | TTR | TTR amyloidosis | Enrollment begins H1, 2010 |
Opko | Bevasiranib (phase III) | Terminated | VEGF-A | AMD | 522 |
Allergan/SIRNA | AGN211745 (phase II) | Terminated | VEGFRI | AMD | 164 |
Tekmira | ApoB SNALP (phase I) | Completed | ApoB | Hypercholesterolemia | 23 |
Transderm | TD101 (phase I completed) | Completed | Mutant K6a | Pachyonychia congenita | 1 |
Univ. Duisberg-Essen‡ | Bcr-abl (phase I completed) | Unknown | Bcr-abl oncogene | CML | 1 |